ATLANTA--(BUSINESS WIRE)--NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of ambulatory-focused technology solutions, today announced its operating results for the fiscal third quarter ended December 31, 2021.
Fiscal 2022 Third Quarter Highlights
- Total revenue for the fiscal 2022 third quarter was $149.7 million compared to $141.8 million for the same period a year ago, or 6 percent growth.
- Recurring revenue accounted for 90 percent of total revenue, or $134.5 million, growing 5 percent over the year ago period.
- Subscription services revenue in the fiscal third quarter generated $41.2 million, or 8 percent growth over the prior year period, driven by demand for NGE SaaS and Virtual Visit solutions.
- Fiscal 2022 third quarter bookings, which reflects annual contract value, was $37.7 million.
- Fully diluted net income per share in the fiscal 2022 third quarter was $0.08 compared to net income of $0.01 per share the same period a year ago.
- On a non-GAAP basis, fully diluted earnings per share for the fiscal 2022 third quarter was $0.24 compared to $0.26 for the same period a year ago.
- In October, the Board approved a $60 million share repurchase program.
“This is an exciting time at NextGen Healthcare. Fiscal third quarter reflects more than record revenue driven by the strength and breadth of our tailored offering. NextGen has a refreshed board of directors with deep executive and diverse healthcare and technology experience. We have attracted top talent at key positions in the executive team to enhance an already strong group. And as a unit, we initiated actions to accelerate performance on our strategic growth objectives,” said David Sides, President and Chief Executive Officer of NextGen Healthcare. “In my first four months on the job, I have prioritized listening to our clients and shareholders and have come away from these discussions, enthused about the overall independent ambulatory market and NextGen’s ability to lead its transformation. I look forward to leveraging our strong foundation to accelerate profitable growth and long-term shareholder value.”
NextGen Healthcare updates its fiscal year 2022 financial guidance as follows:
- Increase revenue to between $591 and $595 million, from between $584 and $590 million prior
- Increase non-GAAP earnings per share range to between $0.96 and $1.00 from between $0.90 and $0.96 prior
Conference Call Information
NextGen Healthcare will host a conference call to discuss its fiscal year 2022 third quarter operating results today at 5:00 p.m. Eastern time. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 866-831-8713 or 203-518-9822 for international callers and referencing participant code NXGNQ322 approximately 15 minutes prior to the call. A recording of the live webcast will be available on investor.nextgen.com after the call. It will be archived for 90 days.
SAFE HARBOR PROVISIONS FOR FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements within the meaning of the federal securities laws, including but not limited to, statements regarding future events including but not limited to the COVID-19 pandemic, developments in the healthcare sector and regulatory framework, share repurchases, the Company's future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future (including, without limitation, statements concerning revenue, net income, and earnings per share). Risks and uncertainties exist that may cause the results to differ materially from those set forth in these forward-looking statements. Factors that could cause the anticipated results to differ from those described in the forward-looking statements and additional risks and uncertainties are set forth in Part I, Item A of our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, including but not limited to: volatility and uncertainty in the global economy, financial markets and on our customers in light of the continuing COVID-19 pandemic, including the potential (i) slowdown or shutdown of preventive and elective medical procedures, (ii) delay in the contracting for additional products and services by our customers and (iii) delay in the sales cycle for new customers; the volume and timing of systems sales and installations; length of sales cycles and the installation process; the possibility that products will not achieve or sustain market acceptance; seasonal patterns of sales and customer buying behavior; impact of incentive payments under The American Recovery and Reinvestment Act on sales and the ability of the Company to meet continued certification requirements; uncertainties related to the future impact of U.S. tax reform; the impact of governmental and regulatory agency investigations; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; undetected errors or bugs in software; product liability; changing economic, political or regulatory influences in the health-care industry; changes in product-pricing policies; availability of third-party products and components; competitive pressures including product offerings, pricing and promotional activities; the Company's ability or inability to attract and retain qualified personnel; possible regulation of the Company's software by the U.S. Food and Drug Administration; changes of accounting estimates and assumptions used to prepare the prior periods' financial statements; disruptions caused by acquisitions of companies, products, or technologies; the extent to which the COVID-19 pandemic and measures taken in response thereto could adversely affect our financial condition and results of operations; and general economic conditions. A significant portion of the Company's quarterly sales of software product licenses and computer hardware is concluded in the last month of a fiscal quarter, generally with a concentration of such revenues earned in the final ten business days of that month. Due to these and other factors, the Company's revenues and operating results are very difficult to forecast. A major portion of the Company's costs and expenses, such as personnel and facilities, are of a fixed nature and, accordingly, a shortfall or decline in quarterly and/or annual revenues typically results in lower profitability or losses. As a result, comparison of the Company's period-to-period financial performance is not necessarily meaningful and should not be relied upon as an indicator of future performance. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
USE OF NON-GAAP FINANCIAL MEASURES
This news release contains certain non-GAAP (Generally Accepted Accounting Principles) financial measures, which are provided only as supplemental information. Investors should consider these non-GAAP financial measures only in conjunction with the comparable GAAP financial measures. These non-GAAP measures are not in accordance with or a substitute for U.S. GAAP. Pursuant to the requirements of Regulation G, the Company has provided a reconciliation of non-GAAP financial measures to the most directly comparable financial measure in the accompanying financial tables. Other companies may calculate non-GAAP measures differently than NextGen Healthcare, Inc., which limits comparability between companies. The Company believes that its presentation of non-GAAP diluted earnings per share provides useful supplemental information to investors and management regarding the Company's financial condition and results. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. The Company calculates free cash flow by as total net cash provided by operating activities, net of cash used for the additions of capitalized software costs and equipment and improvements. The Company calculates net debt as line of credit less cash and cash equivalents. The Company calculates non-GAAP diluted earnings per share by excluding net acquisition costs, amortization of acquired intangible assets, amortization of deferred debt issuance costs, impairment of assets, restructuring costs, shareholder disputes and related costs, net of insurance, which include net securities litigation defense, proxy contest, and related costs, share-based compensation, and other non-run-rate expenses from GAAP income before provision for income taxes.
The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate expected to be applied to each quarter of fiscal year 2022 is 20.0%. The determination of this rate is based on the consideration of both historic and projected financial results. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occur that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.
The Company’s future period guidance in this release includes adjustments for items not indicative of the Company’s core operations. Such adjustments are generally expected to be of a nature similar to those adjustments applied to the Company’s historic GAAP financial results in the determination of the Company’s non-GAAP diluted earnings per share. Such adjustments, however, may be affected by changes in ongoing assumptions and judgments as to the items that are excluded in the calculation of non-GAAP adjusted net income and adjusted diluted earnings per share, as described in this release. The exact amount and probable significance of these adjustments, including net acquisition costs, impairment of assets, restructuring costs, shareholder disputes and related costs, which include net securities litigation defense, proxy contest, and related costs, and other non-run-rate expenses, are not currently determinable without unreasonable efforts, but may be significant. These items cannot be reliably quantified or forecasted due to the combination of their historic and expected variability. It is therefore not practicable to reconcile this non-GAAP guidance to the most comparable GAAP measures.
About NextGen Healthcare, Inc.
NextGen Healthcare, Inc. (Nasdaq: NXGN) is a leading provider of ambulatory-focused technology solutions. We are empowering the transformation of ambulatory care—partnering with medical, behavioral and dental providers in their journey to value-based care to make healthcare better for everyone. We go beyond EHR and PM. Our integrated solutions help increase clinical productivity, enrich the patient experience, and ensure healthy financial outcomes. We believe in better. Learn more at nextgen.com, and follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.
NEXTGEN HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data) (Unaudited) |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recurring |
$ |
134,496 |
|
|
$ |
128,243 |
|
|
$ |
402,486 |
|
|
$ |
373,456 |
|
Software, hardware, and other non-recurring |
|
15,225 |
|
|
|
13,509 |
|
|
|
42,605 |
|
|
|
39,177 |
|
Total revenues |
|
149,721 |
|
|
|
141,752 |
|
|
|
445,091 |
|
|
|
412,633 |
|
Cost of revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recurring |
|
58,033 |
|
|
|
54,204 |
|
|
|
172,312 |
|
|
|
157,539 |
|
Software, hardware, and other non-recurring |
|
7,978 |
|
|
|
6,800 |
|
|
|
23,085 |
|
|
|
18,924 |
|
Amortization of capitalized software costs and acquired intangible assets |
|
8,193 |
|
|
|
9,320 |
|
|
|
24,246 |
|
|
|
29,180 |
|
Total cost of revenue |
|
74,204 |
|
|
|
70,324 |
|
|
|
219,643 |
|
|
|
205,643 |
|
Gross profit |
|
75,517 |
|
|
|
71,428 |
|
|
|
225,448 |
|
|
|
206,990 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative |
|
47,238 |
|
|
|
48,972 |
|
|
|
159,615 |
|
|
|
131,659 |
|
Research and development costs, net |
|
19,390 |
|
|
|
18,197 |
|
|
|
57,229 |
|
|
|
54,111 |
|
Amortization of acquired intangible assets |
|
881 |
|
|
|
1,112 |
|
|
|
2,643 |
|
|
|
3,336 |
|
Impairment of assets |
|
— |
|
|
|
2,215 |
|
|
|
1,577 |
|
|
|
2,215 |
|
Restructuring costs |
|
— |
|
|
|
— |
|
|
|
539 |
|
|
|
2,562 |
|
Total operating expenses |
|
67,509 |
|
|
|
70,496 |
|
|
|
221,603 |
|
|
|
193,883 |
|
Income from operations |
|
8,008 |
|
|
|
932 |
|
|
|
3,845 |
|
|
|
13,107 |
|
Interest income |
|
50 |
|
|
|
9 |
|
|
|
79 |
|
|
|
27 |
|
Interest expense |
|
(321 |
) |
|
|
(631 |
) |
|
|
(958 |
) |
|
|
(2,873 |
) |
Other expense, net |
|
(9 |
) |
|
|
(15 |
) |
|
|
(43 |
) |
|
|
(17 |
) |
Income before provision for (benefit of) income taxes |
|
7,728 |
|
|
|
295 |
|
|
|
2,923 |
|
|
|
10,244 |
|
Provision for (benefit of) income taxes |
|
2,535 |
|
|
|
(169 |
) |
|
|
1,653 |
|
|
|
149 |
|
Net income: |
$ |
5,193 |
|
|
$ |
464 |
|
|
$ |
1,270 |
|
|
$ |
10,095 |
|
Net income per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
$ |
0.08 |
|
|
$ |
0.01 |
|
|
$ |
0.02 |
|
|
$ |
0.15 |
|
Diluted |
$ |
0.08 |
|
|
$ |
0.01 |
|
|
$ |
0.02 |
|
|
$ |
0.15 |
|
Weighted-average shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
67,958 |
|
|
66,943 |
|
|
|
67,514 |
|
|
|
66,644 |
||
Diluted |
|
68,167 |
|
|
67,140 |
|
|
67,851 |
|
|
66,649 |
||||
NEXTGEN HEALTHCARE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except per share data) (Unaudited) |
||||||||
|
|
December 31, 2021 |
|
March 31, 2021 |
||||
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
49,429 |
|
|
$ |
73,295 |
|
Restricted cash and cash equivalents |
|
|
4,921 |
|
|
|
5,280 |
|
Accounts receivable, net |
|
|
70,080 |
|
|
|
77,541 |
|
Contract assets |
|
|
24,246 |
|
|
|
19,481 |
|
Income taxes receivable |
|
|
6,966 |
|
|
|
765 |
|
Prepaid expenses and other current assets |
|
|
30,098 |
|
|
|
31,282 |
|
Total current assets |
|
|
185,740 |
|
|
|
207,644 |
|
Equipment and improvements, net |
|
|
10,818 |
|
|
|
14,539 |
|
Capitalized software costs, net |
|
|
41,719 |
|
|
|
41,474 |
|
Operating lease assets |
|
|
13,047 |
|
|
|
18,446 |
|
Deferred income taxes, net |
|
|
19,439 |
|
|
|
19,474 |
|
Contract assets, net of current |
|
|
1,997 |
|
|
|
1,976 |
|
Intangibles, net |
|
|
27,402 |
|
|
|
36,700 |
|
Goodwill |
|
|
267,212 |
|
|
|
267,212 |
|
Other assets |
|
|
37,960 |
|
|
|
37,021 |
|
Total assets |
|
$ |
605,334 |
|
|
$ |
644,486 |
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
15,232 |
|
|
$ |
11,378 |
|
Contract liabilities |
|
|
54,879 |
|
|
|
52,863 |
|
Accrued compensation and related benefits |
|
|
42,019 |
|
|
|
50,374 |
|
Income taxes payable |
|
|
405 |
|
|
|
584 |
|
Operating lease liabilities |
|
|
8,437 |
|
|
|
12,735 |
|
Other current liabilities |
|
|
49,436 |
|
|
|
52,699 |
|
Total current liabilities |
|
|
170,408 |
|
|
|
180,633 |
|
Deferred compensation |
|
|
7,671 |
|
|
|
6,620 |
|
Operating lease liabilities, net of current |
|
|
12,781 |
|
|
|
18,453 |
|
Other noncurrent liabilities |
|
|
3,331 |
|
|
|
7,136 |
|
Total liabilities |
|
|
194,191 |
|
|
|
212,842 |
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
Shareholders' equity: |
|
|
|
|
|
|
|
|
Common stock, $0.01 par value; authorized 100,000 shares; issued and outstanding 66,865 and 67,069 shares at December 31, 2021 and March 31, 2021, respectively |
|
|
690 |
|
|
|
671 |
|
Treasury stock, at cost, 2,170 shares at December 31, 2021 |
|
|
(35,874 |
) |
|
|
— |
|
Additional paid-in capital |
|
|
318,356 |
|
|
|
304,263 |
|
Accumulated other comprehensive loss |
|
|
(1,933 |
) |
|
|
(1,924 |
) |
Retained earnings |
|
|
129,904 |
|
|
|
128,634 |
|
Total shareholders' equity |
|
|
411,143 |
|
|
|
431,644 |
|
Total liabilities and shareholders' equity |
$ |
605,334 |
|
$ |
644,486 |
|
||
NEXTGEN HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
$ |
5,193 |
|
|
$ |
464 |
|
|
$ |
1,270 |
|
|
$ |
10,095 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of capitalized software costs |
|
5,975 |
|
|
|
4,975 |
|
|
|
17,592 |
|
|
|
14,828 |
|
Amortization of debt issuance costs |
|
127 |
|
|
|
177 |
|
|
|
381 |
|
|
|
532 |
|
Amortization of other intangibles |
|
3,100 |
|
|
|
5,456 |
|
|
|
9,298 |
|
|
|
17,688 |
|
Change in fair value of contingent consideration |
|
7 |
|
|
|
25 |
|
|
|
7 |
|
|
|
75 |
|
Deferred income taxes |
|
6 |
|
|
|
(15 |
) |
|
|
35 |
|
|
|
(42 |
) |
Depreciation |
|
1,625 |
|
|
|
2,151 |
|
|
|
5,406 |
|
|
|
6,088 |
|
Excess tax deficiency from share-based compensation |
|
194 |
|
|
|
(71 |
) |
|
|
834 |
|
|
|
870 |
|
Impairment of assets |
|
— |
|
|
|
2,215 |
|
|
|
1,577 |
|
|
|
2,215 |
|
Loss on disposal of equipment and improvements |
|
— |
|
|
|
27 |
|
|
|
77 |
|
|
|
27 |
|
Non-cash operating lease costs |
|
1,368 |
|
|
|
1,732 |
|
|
|
4,455 |
|
|
|
5,153 |
|
Provision for bad debts |
|
463 |
|
|
|
645 |
|
|
|
1,142 |
|
|
|
2,044 |
|
Share-based compensation |
|
7,050 |
|
|
|
5,933 |
|
|
|
18,685 |
|
|
|
16,763 |
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
1,445 |
|
|
|
(2,284 |
) |
|
|
6,319 |
|
|
|
1,221 |
|
Contract assets |
|
(3,731 |
) |
|
|
(1,577 |
) |
|
|
(4,786 |
) |
|
|
(4,058 |
) |
Accounts payable |
|
2,484 |
|
|
|
961 |
|
|
|
3,592 |
|
|
|
(2,795 |
) |
Contract liabilities |
|
1,373 |
|
|
|
213 |
|
|
|
2,016 |
|
|
|
(8,131 |
) |
Accrued compensation and related benefits |
|
7,966 |
|
|
|
7,862 |
|
|
|
(8,355 |
) |
|
|
16,210 |
|
Income taxes |
|
2,110 |
|
|
|
(1,411 |
) |
|
|
(7,214 |
) |
|
|
(3,494 |
) |
Deferred compensation |
|
396 |
|
|
|
484 |
|
|
|
1,051 |
|
|
|
1,324 |
|
Operating lease liabilities |
|
(4,702 |
) |
|
|
(4,819 |
) |
|
|
(10,062 |
) |
|
|
(10,043 |
) |
Other assets and liabilities |
|
(16,292 |
) |
|
|
4,803 |
|
|
|
(6,684 |
) |
|
|
9,408 |
|
Net cash provided by operating activities |
|
16,157 |
|
|
|
27,946 |
|
|
|
36,636 |
|
|
|
75,978 |
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additions to capitalized software costs |
|
(6,124 |
) |
|
|
(6,831 |
) |
|
|
(17,837 |
) |
|
|
(18,914 |
) |
Additions to equipment and improvements |
|
(352 |
) |
|
|
(782 |
) |
|
|
(2,037 |
) |
|
|
(1,546 |
) |
Acquisition related working capital adjustment payments |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(206 |
) |
Net cash used in investing activities |
|
(6,476 |
) |
|
|
(7,613 |
) |
|
|
(19,874 |
) |
|
|
(20,666 |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from line of credit |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
50,000 |
|
Repayments on line of credit |
|
— |
|
|
|
(35,000 |
) |
|
|
— |
|
|
|
(150,000 |
) |
Payment of contingent consideration related to acquisitions |
|
(540 |
) |
|
|
— |
|
|
|
(540 |
) |
|
|
— |
|
Proceeds from issuance of shares under employee plans |
|
(232 |
) |
|
|
1,199 |
|
|
|
877 |
|
|
|
1,997 |
|
Repurchase of common stock |
|
(35,874 |
) |
|
|
— |
|
|
|
(35,874 |
) |
|
|
— |
|
Payments for taxes related to net share settlement of equity awards |
|
(249 |
) |
|
|
(1,646 |
) |
|
|
(5,450 |
) |
|
|
(3,897 |
) |
Net cash used in financing activities |
|
(36,895 |
) |
|
|
(35,447 |
) |
|
|
(40,987 |
) |
|
|
(101,900 |
) |
Net decrease in cash, cash equivalents, and restricted cash |
|
(27,214 |
) |
|
|
(15,114 |
) |
|
|
(24,225 |
) |
|
|
(46,588 |
) |
Cash, cash equivalents, and restricted cash at beginning of period |
|
81,564 |
|
|
|
108,845 |
|
|
|
78,575 |
|
|
|
140,319 |
|
Cash, cash equivalents, and restricted cash at end of period |
$ |
54,350 |
|
$ |
93,731 |
|
$ |
54,350 |
|
$ |
93,731 |
|
|||
NEXTGEN HEALTHCARE, INC. SUPPLEMENTAL FINANCIAL INFORMATION (In thousands) |
|||||||||||||||
The following table presents our revenues disaggregated by our major revenue categories and by occurrence: |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Recurring revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subscription services |
$ |
41,158 |
|
|
$ |
37,958 |
|
|
$ |
120,581 |
|
|
$ |
110,185 |
|
Support and maintenance |
|
38,246 |
|
|
|
37,914 |
|
|
|
115,736 |
|
|
|
114,537 |
|
Managed services |
|
28,861 |
|
|
|
27,395 |
|
|
|
87,798 |
|
|
|
76,106 |
|
Electronic data interchange and data services |
|
26,231 |
|
|
|
24,976 |
|
|
|
78,371 |
|
|
|
72,628 |
|
Total recurring revenues |
|
134,496 |
|
|
|
128,243 |
|
|
|
402,486 |
|
|
|
373,456 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Software, hardware, and other non-recurring revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Software license and hardware |
|
8,920 |
|
|
|
7,908 |
|
|
|
24,202 |
|
|
|
20,662 |
|
Other non-recurring services |
|
6,305 |
|
|
|
5,601 |
|
|
|
18,403 |
|
|
|
18,515 |
|
Total software, hardware and other non-recurring revenues |
|
15,225 |
|
|
|
13,509 |
|
|
|
42,605 |
|
|
|
39,177 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
$ |
149,721 |
|
|
$ |
141,752 |
|
|
$ |
445,091 |
|
|
$ |
412,633 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recurring revenues as a percentage of total revenues |
|
89.8 |
% |
|
90.5 |
% |
|
90.4 |
% |
|
90.5 |
% |
|||
NEXTGEN HEALTHCARE, INC. NON-GAAP FINANCIAL MEASURES (In thousands, except per share data) |
|||||||||||||||
RECONCILIATION OF NON-GAAP DILUTED EARNINGS PER SHARE |
|||||||||||||||
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Income before provision for income taxes - GAAP |
$ |
7,728 |
|
|
$ |
295 |
|
|
$ |
2,923 |
|
|
$ |
10,244 |
|
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition costs, net |
|
— |
|
|
|
118 |
|
|
|
— |
|
|
|
380 |
|
Amortization of acquired intangible assets |
|
3,099 |
|
|
|
5,456 |
|
|
|
9,298 |
|
|
|
17,688 |
|
Amortization of deferred debt issuance costs |
|
127 |
|
|
|
177 |
|
|
|
381 |
|
|
|
532 |
|
Impairment of assets |
|
— |
|
|
|
2,215 |
|
|
|
1,577 |
|
|
|
2,215 |
|
Restructuring costs |
|
— |
|
|
|
— |
|
|
|
539 |
|
|
|
2,562 |
|
Shareholder disputes and related costs, net of insurance |
|
2,224 |
|
|
|
5,955 |
|
|
|
29,216 |
|
|
|
10,214 |
|
Share-based compensation |
|
7,050 |
|
|
|
5,933 |
|
|
|
18,685 |
|
|
|
16,763 |
|
Other non-run-rate expenses* |
|
351 |
|
|
|
1,669 |
|
|
|
4,379 |
|
|
|
4,134 |
|
Total adjustments to GAAP income before provision for income taxes: |
|
12,851 |
|
|
|
21,523 |
|
|
|
64,075 |
|
|
|
54,488 |
|
Income before provision for income taxes - Non-GAAP |
|
20,579 |
|
|
|
21,818 |
|
|
|
66,998 |
|
|
|
64,732 |
|
Provision for income taxes |
|
4,116 |
|
|
|
4,363 |
|
|
|
13,400 |
|
|
|
12,946 |
|
Net income - Non-GAAP |
$ |
16,463 |
|
|
$ |
17,455 |
|
|
$ |
53,598 |
|
|
$ |
51,786 |
|
Diluted net income per share - Non-GAAP |
$ |
0.24 |
|
|
$ |
0.26 |
|
|
$ |
0.79 |
|
|
$ |
0.78 |
|
Weighted-average shares outstanding (diluted): |
|
68,167 |
|
|
|
67,140 |
|
|
|
67,851 |
|
|
|
66,649 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Other non-run-rate expenses for the three months ended December 31, 2021 consist primarily of $312 excess lease-related expense for vacated facilities and other costs and $39 of professional services costs not related to core operations.
Other non-run-rate expenses for the three months ended December 31, 2020 consist primarily of $1,204 excess lease-related expense for vacated facilities, lease termination costs, and other costs, including retention bonuses and severance expense, related to the restructuring plan and $465 of professional services costs not related to core operations.
Other non-run-rate expenses for the nine months ended December 31, 2021 consist primarily of $1,135 excess lease-related expense for vacated facilities, lease termination costs, and other costs, including retention bonuses, related to the restructuring plan and $2,707 of executive transition costs, including severance and other costs related to the departure of the CEO, $498 of incremental costs and penalties primarily due to the cancellation of certain events directly associated with the COVID-19 pandemic, and $39 of professional services costs not related to core operations.
Other non-run-rate expenses for the nine months ended December 31, 2020 consist primarily of $2,631 excess lease-related expense for vacated facilities, lease termination costs, and other costs, including retention bonuses and severance expense, related to the restructuring plan, $1,404 of professional services costs not related to core operations, and $99 of incremental costs and penalties primarily due to the cancellation of certain events directly associated with the COVID-19 pandemic. |
|||||||||||||||
RECONCILIATION OF FREE CASH FLOW
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Net cash provided by operating activities |
$ |
16,157 |
|
|
$ |
27,946 |
|
|
$ |
36,636 |
|
|
$ |
75,978 |
|
Additions to capitalized software costs |
|
(6,124 |
) |
|
|
(6,831 |
) |
|
|
(17,837 |
) |
|
|
(18,914 |
) |
Additions to equipment and improvements |
|
(352 |
) |
|
|
(782 |
) |
|
|
(2,037 |
) |
|
|
(1,546 |
) |
Free cash flow |
$ |
9,681 |
|
|
$ |
20,333 |
|
|
$ |
16,762 |
|
|
$ |
55,518 |
|
